pdufa.bio
CalendarDecisionsReadoutsPatents
Drug IndexStocksScreenerConferencesAdvisory Committees
StudiesRun-up by YearLearnGlossaryMethodologyAPIAccount
Pro
Home › FDA Decisions › PHAR 2026-02-01

PHAR FDA Decision CRL · 2026-02-01

Updated ·next FDA decision on the calendar
clinical/data CRL: Pharming Joenja pediatric sNDA CRL

Price into the decision (T-120)

PDUFA 2/1/26$21.18$11.258/15/25
Daily close, T-120 (8/15/25) through T+5. Run-up high $21.18 on 1/27/26, low $11.25 on 8/20/25 (T-120 to T-1). FDA decision 2/1/26. Historical price action, not a forecast.

Decision facts

FDA decision date2026-02-01
Outcome✗ CRL✓ source-verified
Decision-day move-17.0%
T-120 run-up (low→high)+46.0% ($13.1→$21.18)
CRL reasonclinical/data: Pharming Joenja pediatric sNDA CRL
Primary sourceView filing ↗
Market-cap tierSmall
Cohort decision-day move (history)3.6% median (n=280)

Cohort move is the historical median absolute decision-day move for this market-cap tier across our run-up study. History, not a prediction.

See the full 2026 PDUFA calendar →

Questions

Was source-verified approved by the FDA?

Not in this review cycle. On February 1, 2026 the FDA issued a Complete Response Letter, declining to approve the application for source-verified in its current form. A CRL is not final; the primary source is linked on this page.

How did PHAR stock react to the FDA decision?

On the decision day PHAR moved -17.0%. That is the recorded reaction to this specific event -- historical measurement, not a prediction, and not investment advice.